GENETIC POLYMORPHISMS IN THE HUMAN NEUROKININ 1 RECEPTOR GENE AND THEIR USES IN DIAGNOSIS AND TREATMENT OF DISEASES

Abstract: This invention relates to nine single nucleotide polymorphisms in the human NK1R gene (1 in the regulatory region, 2 in coding regions, 2 in flanking intron sequence, 4 in the 3' UTR region) and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the NK1R gene and to the use of said polymorphism in the diagnosis and treatment of NK1R ligand mediated diseases, such as asthma.

Description: GENETIC POLYMORPHISMS IN THE HUMAN NEUROKININ 1 RECEPTOR GENE AND THEIR USES IN DIAGNOSIS AND TREATMENT OF DISEASES This invention relates to polymorphisms in the human NKIR gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and 5 materials for analysing allelic variation in the NKIR gene and to the use of said polymorphism in the diagnosis and treatment of NKIR ligand mediated diseases, such as asthma. The reader is referred to the following publications for background information: Primary structure and gene organization of human substance P and neuromedin K receptors, K 10 Takahashi et al Eur J Biochem 204, 1025-1033 (1992); Differential activation of intracellular effector by two isoforms of the human neurokinin-1 receptor, TM Fong et al Molecular Pharmacology 41,24-30 (1992); Human Substance P receptor (NK-1): organisation of the gene, chromosome localization, and functional expression of cDNA clones, Gerard et al Biochemistry 30, 10640-10646 (1991); Isolation and characterization of the human lung NK- 15 1 receptor cDNA, Hopkins et al, Biochem Biophys Res Commun 180,110-1117 (1991); Mutational analysis of neurokinin receptor function. TM Fong et al Can J Physiol Pharmacol 73, 860-865 (1995); Structure and function of G protein-coupled receptors, CD Strader et al Annual Reviews Biochemistry 63,101-132 (1994); The evolution and structure of aminergic G protein-coupled receptors, D Donnelly et al Receptors and Channels 2, 61-78 (1994). 20 NKIR polypeptide is known to exist in 2 isoforms, which are possibly alternatively spliced variants of a single NKIR gene, see TM Fong et al Molecular Pharmacology 41,24-30 (1992). A cDNA encoding NKIR has been published in International patent application WO 92/16547, Children's Medical Center; and in European patent application EP 510 878, Merck. The complete genomic sequence of NKIR is not presently known but regions thereof 25 containing exons 1, 3 & 5 have been published by EMBL as follows: Exon 1, Accession Number X 65177, 2472 bp; Exon 3, Accession Number X65179, 373 bp; Exon 5, Accession Number X65181, 3929 bp. Apart from Accession Number X 65177, all positions herein relate to the positions indicated therein unless stated otherwise or apparent from the context. The inventors have discovered that part of the sequence presented in EMBL Accession 30 Number X65177 is incorrect. Sequencing of genomic PCR products by the present inventors, has shown that the nucleotide sequence from positions 262 - 758 of EMBL Accession Number X65177 is incorrect and a Blast search of the data bases has shown that this erroneous sequence actually corresponds to positions 1231-1729 of EMBL Accession Number U37688 which encodes a gene similar to the human c-myc proto-oncogene. None of the specific polymorphisms identified herein however, fall within this erroneous sequence. A sequence containing the promoter region of the human NKIR gene has been published in "Structure, expression and second messenger- mediated regulation of the human and rat substance P receptors and their genes" JE Krause et al Regulatory Peptides 46 , 59-66 (1993), (see Figure 2 - Conservation of the human and rat Substance P receptor gene putative promoter regions). The present inventors have confirmed that this sequence is correct. No accession number has been assigned to this published sequence. In view of the sequence error in EMBL X 65177, the corrected sequence is included herein as SEQ ID No. 1. This sequence has been used as the reference sequence for locating the position of the novel promoter and exon 1 (+ intron junction region) polymorphic variants of the NKIR gene identified herein. With respect to SEQ ID No.l, nucleotides 1 - 261 correspond to sequences 1 - 261 in X 65177, sequence 262-833 replaces sequence 262-758 of X 65177 (resulting in an addition of 75 nucleotides to the complete sequence length) and sequence 834 - 2547 corresponds to sequence 759- 2472 of X 65177. Exon 1 ATG starts at position 2029 and ends at position 2417. One approach is to use knowledge of polymorphisms to help identify patients most suited to therapy with particular pharmaceutical agents (this is often termed "pharmacogenetics") . Pharmacogenetics can also be used in pharmaceutical research to assist the drug selection process. Polymorphisms are used in mapping the human genome and to elucidate the genetic component of diseases. The reader is directed to the following references for background details on pharmacogenetics and other uses of polymorphism detection: Linder et al. (1997), Clinical Chemistry, 43, 254; Marshall (1997), Nature Biotechnology, 15, 1249; International Patent Application WO 97/40462, Spectra Biomedical; and Schafer et al. (1998), Nature Biotechnology, 16, 33. A haplotype is a set of alleles found at linked polymorphic sites (such as within a gene) on a single (paternal or maternal) chromosome. If recombination within the gene is random, there may be as many as 2 n haplotypes, where 2 is the number of alleles at each SNP and n is the number of SNPs. One approach to identifying mutations or polymorphisms which are correlated with clinical response is to carry out an association study using all the haplotypes that can be identified in the population of interest. The frequency of each haplotype is limited by the frequency of its rarest allele, so that SNPs with low frequency alleles are particularly useful as markers of low frequency haplotypes. As particular mutations or polymorphisms associated with certain clinical features, such as adverse or abnormal events, are likely to be 5 of low frequency within the population, low frequency SNPs may be particularly useful in identifying these mutations (for examples see: Linkage disequilibrium at the cystathionine beta synthase (CBS) locus and the association between genetic variation at the CBS locus and plasma levels of homocysteine. Ann Hum Genet (1998) 62:481-90, De Stefano V, Dekou V, Nicaud V, Chasse IF, London J, Stansbie D, Humphries SE, and Gudnason V; and Variation 10 at the von willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood (1999) 93:4277-83, Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D). Clinical trials have shown that patient response to treatment with pharmaceuticals is often heterogeneous. Thus there is a need for improved approaches to pharmaceutical agent design 15 and therapy. Point mutations in polypeptides will be referred to as follows: natural amino acid (using 1 or 3 letter nomenclature) , position, new amino acid. For (a hypothetical) example, "D25K" or "Asp25Lys" means that at position 25 an aspartic acid (D) has been changed to lysine (K). Multiple mutations in one polypeptide will be shown between square brackets with individual 0 mutations separated by commas. The present invention is based on the discovery of single nucleotide polymorphisms (SNPs) in the NKIR gene. As defined herein, the NKIR gene includes exon coding sequence, intron sequences intervening the exon sequences and, 3' and 5' untranslated region (3' UTR and 5' UTR) sequences, including the promoter element of the NKIR gene. 25 According to one aspect of the present invention there is provided a method for the diagnosis of a single nucleotide polymorphism in NKIR in a human, which method comprises determining the sequence of the nucleic acid of the human at one or more of positions: 2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 30 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; and determining the status of the human by reference to polymorphism in the NKIR gene. According to another aspect of the present invention there is provided a method for diagnosis of a single nucleotide polymoφhism in NKIR in a human, which method comprises determining the sequence of the nucleic acid of the human at one or more positions: 2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177; 5 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 495 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181; 10 600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; and determining the status of the human by reference to polymoφhism in NKIR or its 3 ' untranslated region. According to another aspect of the present invention there is provided a method for 15 diagnosis of one or more single nucleotide polymoφhism(s) in NKIR gene in a human, which method comprises determining the sequence of the nucleic acid of the human at one or more positions: 2361 in exon 1 as defined by the position in SEQ ID No. 1; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 20 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 25 809 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181 ; 1371 in the promoter element as defined by the position in SEQ ID No. 1 ; and determining the status of the human by reference to polymoφhism in NKIR. The term human includes both a human having or suspected of having a NKIR ligand mediated disease and an asymptomatic human who may be tested for predisposition or 30 susceptibility to such disease. At each position the human may be homozygous for an allele or the human may be a heterozygote. In one embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymoφhism at position 2361 in exon 1 is presence of C and/or T. In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymoφhism at position 271 near exon 3 is presence of G and/or T. In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymoφhism at position 272 near exon 3 is presence of A and/or a single base deletion at this position. In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymoφhism at position 245 in exon 5 is presence of C and/or a single base deletion at this position. This results in premature termination and loss of C-terminal 26 amino acids (see Example 1 below). Testing for the presence of this polymoφhism is especially preferred because, without wishing to be bound by theoretical considerations, of its association with a significant loss of amino acids. In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymoφhism at position 461 in the 3 'UTR is presence of G and/or C. In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymoφhism at position 495 in the 3 'UTR is the presence of T and/or a single base insertion of A at this position. In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymoφhism at position 600 in the 3 'UTR is presence of A and/or G. In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymoφhism at position 809 in the 3 'UTR is presence of C and/or T. In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymoφhism at position 1371 in the promoter element is presence of A and/or G. When considering positional relationships in the presence of a single base deletion or insertion the introduction of an appropriate gap is required in accordance with established techniques. In another aspect of the invention we provide a method for the diagnosis of NKIR 5 ligand-mediated disease, which method comprises: i) obtaining sample nucleic acid from an individual, detecting the presence or absence of a variant nucleotide at one or more of positions: 2361 in exon 1 as defined by the position in SEQ ID No. 1; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 10 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181 ; 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 15 809 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181 ; 1371 in the promoter element as defined by the position in SEQ ID No. 1 ; and determining the status of the human by reference to polymoφhism in NKIR. The method for diagnosis is preferably one in which the sequence is determined by a method selected from allele specific amplification (i.e. ARMS™-allele specific amplification; 20 ARMS referring to amplification refractory mutation system), allele specific hybridisation (ASH), oligonucleotide ligation assay (OLA) and restriction fragment length polymoφhism (RFLP). The status of the human may be determined by reference to allelic variation at any one, two, three, four, five, six, seven, eight or all nine positions. The status of the human may also 25 be determined by one or more of the specific polymoφhisms identified herein in combination with one or more other SNP's. NK1 antagonists have been explored by Glaxo, Pfizer, Merck, Parke-Davis, Lilly, RPR, and Sanofi, primarily for CNS indications. In a recent clinical trial it was reported that a single dose of Pfizer CP- 122,721 inhibits emesis associated with chemotherapy and was well 30 tolerated with no adverse effects (Kris et al, JNCI, 89, 817, 1997). Most recently Merck has announced positive Phase II studies with a NK1 antagonist in depression/anxiety. It is believed that a dual NK1/ NK2 receptor antagonist will have some clinical utility, particularly for asthma. As compared with conventional therapies, it is expected that a dual NK1/NK2 receptor antagonist will better control airways hyper-responsiveness and neurogenic inflammation (extravasation and hypersecretion), both of which are characteristic manifestations of asthma. This multifaceted approach improves upon other therapies that are designed to treat only a single clinical manifestation of this disease. Other therapeutic opportunities for NK1/NK2 antagonist exist in pain, migraine, anxiety, depression, urinary incontinence, and inflammatory bowel disease. Four companies have published on mixed NK1 NK2 receptor antagonists. Two of the compounds are peptides: FK-224 (Fujisawa) and SI 6474 (Servier). The other two, MDL- 105,212 (Marion Merrell Dow) and a recent compound from Merck, are structurally related to the selective NK2 antagonist, SR48968 (Sanofi). Neurokinin receptor antagonists have been reviewed by C J Swain (1996) in Exp. Opin. Ther. Patents, 6, 367-378; and by Elliot & Seward (1997) in Exp. Opin. Ther. Patents, 7, 43-54. The test sample of nucleic acid is conveniently a sample of blood, bronchoalveolar lavage fluid, sputum, urine or other body fluid or tissue obtained from an individual. It will be appreciated that the test sample may equally be a nucleic acid sequence corresponding to the sequence in the test sample, that is to say that all or a part of the region in the sample nucleic acid may firstly be amplified using any convenient technique e.g. PCR, before analysis of allelic variation. It will be apparent to the person skilled in the art that there are a large number of analytical procedures which may be used to detect the presence or absence of variant nucleotides at one or more polymoφhic positions of the invention. In general, the detection of allelic variation requires a mutation discrimination technique, optionally an amplification reaction and optionally a signal generation system. Table 1 lists a number of mutation detection techniques, some based on the polymerase chain reaction (PCR). These may be used in combination with a number of signal generation systems, a selection of which is listed in Table 2. Further amplification techniques are listed in Table 3. Many current methods for the detection of allelic variation are reviewed by Nollau et al., Clin. Chem. 43, 1114-1120, 1997; and in standard textbooks, for example "Laboratory Protocols for Mutation Detection", Ed. by U. Landegren, Oxford University Press, 1996 and "PCR", 2 nd Edition by Newton & Graham, BIOS Scientific Publishers Limited, 1997. Abbreviations: Table 1 - Mutation Detection Techniques General: DNA sequencing, Sequencing by hybridisation Scanning: PTT*, SSCP, DGGE, TGGE, Cleavase, Heteroduplex analysis, CMC, Enzymatic mismatch cleavage * Note: not useful for detection of promoter polymoφhisms. Hybridisation Based Solid phase hybridisation: Dot blots, MASDA, Reverse dot blots, Oligonucleotide arrays (DNA Chips) Solution phase hybridisation: Taqman™ - US-5210015 & US-5487972 (Hoffmann-La Roche), Molecular Beacons - Tyagi et al (1996), Nature Biotechnology, 14, 303; WO 95/13399 (Public Health Inst, New York) Extension Based: ARMS™-allele specific amplification (as described in European patent No. EP-B-332435 and US patent No. 5,595,890), ALEX™ - European Patent No. EP 332435 Bl (Zeneca Limited), COPS - Gibbs et al (1989), Nucleic Acids Research, 17, 2347. Incorporation Based: Mini-sequencing, APEX Restriction Enzyme Based: RFLP, Restriction site generating PCR Ligation Based: OLA Other: Invader assay Table 2 - Signal Generation or Detection Systems Fluorescence: FRET, Fluorescence quenching, Fluorescence polarisation - United Kingdom Patent No. 2228998 (Zeneca Limited) Other: Chemiluminescence, Electrochemilummescence, Raman, Radioactivity, Colorimetric, Hybridisation protection assay, Mass spectrometry, SERRS - WO 97/05280 (University of Strathclyde). Table 3 - Further Amplification Methods SSR, NASBA, LCR, SDA, b-DNA Preferred mutation detection techniques include ARMS™-allele specific amplification, ALEX™, COPS, Taqman, Molecular Beacons, RFLP, OLA, restriction site based PCR and FRET techniques. Particularly preferred methods include ARMS™-allele specific amplification, OLA and RFLP based methods. ARMS™-allele specific amplification is an especially preferred method. ARMS™-allele specific amplification (described in European patent No. EP-B-332435, US patent No. 5,595,890 and Newton et al. (Nucleic Acids Research, Vol. 17, p.2503; 1989)), relies on the complementarity of the 3' terminal nucleotide of the primer and its template. The 3' terminal nucleotide of the primer being either complementary or non-complementary to the specific mutation, allele or polymoφhism to be detected. There is a selective advantage for primer extension from the primer whose 3' terminal nucleotide complements the base mutation, allele or polymoφhism. Those primers which have a 3' terminal mismatch with the template sequence severely inhibit or prevent enzymatic primer extension. Polymerase chain reaction or unidirectional primer extension reactions therefore result in product amplification when the 3' terminal nucleotide of the primer complements that of the template, but not, or at least not efficiently, when the 3' terminal nucleotide does not complement that of the template. By way of example, a suitable allele specific primer (ARMS primer) capable of detecting/diagnosing the 2361 "T" polymoφhism in Exon 1 is: 5'-GCAAGTTCCACAACTTCTTT-3' (SEQ ID No. 2). The 3' terminal nucleotide complementing the "A" polymoφhism on the anti-sense template strand facilitates efficient primer extension with the suitable enzyme (preferably one lacking 3 '-5' exonuclease activity). In a further aspect, the diagnostic methods of the invention are used to assess the efficacy of therapeutic compounds in the treatment of NKIR ligand mediated diseases, such as asthma. The polymoφhisms identified in the present invention that occur in intron regions or in the promoter region are not expected to alter the amino acid sequence of the NK1 receptor, but may affect the transcription and/or message stability of the sequences and thus affect the level of the receptors in cells. Assays, for example reporter-based assays, may be devised to detect whether one or more of the above polymoφhisms affect transcription levels and/or message stability. Individuals who carry particular allelic variants of the NKIR gene may therefore exhibit differences in their ability to regulate protein biosynthesis under different physiological conditions and will display altered abilities to react to different diseases. In addition, differences in protein regulation arising as a result of allelic variation may have a direct effect -lion the response of an individual to drug therapy. The diagnostic methods of the invention may be useful both to predict the clinical response to such agents and to determine therapeutic dose. In a further aspect, the diagnostic methods of the invention, are used to assess the predisposition and/or susceptibility of an individual to diseases mediated by NKIR ligands. The present invention may be used to recognise individuals who are particularly at risk from developing these conditions. In a further aspect, the diagnostic methods of the invention are used in the development of new drug therapies which selectively target one or more allelic variants of the NKIR gene. Identification of a link between a particular allelic variant and predisposition to disease development or response to drug therapy may have a significant impact on the design of new drugs. Drugs may be designed to regulate the biological activity of variants implicated in the disease process whilst minimising effects on other variants. In a further diagnostic aspect of the invention the presence or absence of variant nucleotides is detected by reference to the loss or gain of, optionally engineered, sites recognised by restriction enzymes. For example the polymoφhism at position 271 and 272 in exon 3 can be detected by digestion with the restriction enzymes Rsal and Cac8I respectively. Engineered sites include those wherein the primer sequences employed to amplify the target sequence participates along with the nucleotide polymoφhism to create a restriction site (see for example, Example 2 section 2 on 809 polymoφhism in the 3' UTR (SEQ ID No. 6)). According to another aspect of the present invention there is provided a nucleic acid comprising any one of the following polymoφhisms: the nucleic acid sequence of EMBL ACCESSION NO. X 65177 with T at position 2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with T at position 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with a single base deletion at position 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with a single base deletion at position 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at least one of the polymoφhisms. According to another aspect of the present invention there is provided a nucleic acid comprising any one of the following polymoφhisms: the nucleic acid sequence of EMBL ACCESSION NO. X 65177 with T at position 2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with T at position 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with a single base deletion at position 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with a single base deletion at position 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181 ; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with C at position 461 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181 ; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with A inserted at position 495 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181 ; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with G at position 600 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181 ; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with T at position 809 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181; or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at least one of the polymoφhisms. According to another aspect of the present invention there is provided a nucleic acid comprising any one of the following polymoφhism containing sequences: the nucleic acid sequence of SEQ ID No. 1 with T at position 2361 in exon 1 as defined by the position in SEQ ID No. 1; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with T at position 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with a single base deletion at position 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with a single base deletion at position 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with C at position 461 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with A inserted at position 495 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with G at position 600 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181 ; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with T at position 809 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of SEQ ID No. 1 with G at position 1371 in the promoter element as defined by the position in SEQ ID No. 1; or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at least one of the polymoφhisms. Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases. The invention further provides nucleotide primers which can detect the polymoφhisms of the invention. According to another aspect of the present invention there is provided an allele specific primer capable of detecting a NKIR gene polymoφhism of the invention. An allele specific primer is used, generally together with a constant primer, in an amplification reaction such as a PCR reaction, which provides the discrimination between alleles through selective amplification of one allele at a particular sequence position e.g. as used for ARMS™ assays. The allele specific primer is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides. An allele specific primer preferably corresponds exactly with the allele to be detected but derivatives thereof are also contemplated wherein about 6-8 of the nucleotides at the 3' terminus correspond with the allele to be detected and wherein up to 10, such as up to 8, 6, 4, 2, or 1 of the remaining nucleotides may be varied without significantly affecting the properties of the primer. Often the nucleotide at the -2 and/or -3 position (relative to the 3' terminus) is mismatched in order to optimise differential primer binding and preferential extension from the correct allele discriminatory primer only. Primers may be manufactured using any convenient method of synthesis. Examples of such methods may be found in standard textbooks, for example "Protocols for Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology Series; Volume 20; Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1993; 1 st Edition. If required the primer(s) may be labelled to facilitate detection. According to another aspect of the present invention there is provided an allele-specific oligonucleotide probe capable of detecting a NKIR gene polymoφhism of the invention. The allele-specific oligonucleotide probe is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides. The design of such probes will be apparent to the molecular biologist of ordinary skill. Such probes are of any convenient length such as up to 50 bases, up to 40 bases, more conveniently up to 30 bases in length, such as for example 8-25 or 8-15 bases in length. In general such probes will comprise base sequences entirely complementary to the corresponding wild type or variant locus in the gene. However, if required one or more mismatches may be introduced, provided that the discriminatory power of the oligonucleotide probe is not unduly affected. The probes of the invention may carry one or more labels to facilitate detection, such as in Molecular Beacons. According to another aspect of the present invention there is provided a diagnostic kit comprising one or more diagnostic probe(s) of the invention and/or diagnostic primer(s), particularly an allele-specific oligonucleotide primer, of the invention. The diagnostic kits may comprise appropriate packaging and instructions for use in the methods of the invention. Such kits may further comprise appropriate buffer(s) and polymerase(s) such as thermostable polymerases, for example taq polymerase. Such kits may also comprise companion/constant primers and/or control primers or probes. A companion/constant primer is one that is part of the pair of primers used to perform PCR. Such primer usually complements the template strand precisely. In another aspect of the invention, the single nucleotide polymoφhisms of this invention may be used as genetic markers in linkage studies. This particularly applies to the polymoφhism in exon 1 (position 2361 in SEQ ID No. 1) because of its relatively high frequency (see below). Further preferred polymoφhisms of high frequency are at positions 461 and 809 in the 3 'UTR (see example 2 below). Those polymoφhisms that occur relatively infrequently are useful as markers of low frequency haplotypes. According to another aspect of the present invention there is provided an allelic variant of human NKIR polypeptide having a C-terminal deletion of 26 amino acids. According to another aspect of the present invention there is provided a method of treating a human in need of treatment with a NKIR ligand antagonist drug in which the method comprises: i) diagnosis of a single nucleotide polymoφhism in NKIR gene in the human, which diagnosis comprises determining the sequence of the nucleic acid at one or more of positions: 2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 5 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; and determining the status of the human by reference to polymoφhism in the NKIR gene; and ii) administering an effective amount of a NKIR ligand antagonist. 10 According to another aspect of the present invention there is provided a method of treating a human in need of treatment with a NKIR ligand antagonist drug in which the method comprises: (i) diagnosis of a single nucleotide polymoφhism in the NKIR gene in the human, which diagnosis comprises determining the sequence of nucleic acid at one of more of positions: 15 2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 20 495 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181 ; 600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 809 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181 ; and determining the status of the human by reference to polymoφhism in the NKIR gene; and 25 (ii) administering an effective amount of a NKIR ligand antagonist. According to another aspect of the present invention there is provided a method of treating a human in need of treatment with an NKIR ligand antagonist drug in which the method comprises: (i) diagnosis of a single nucleotide polymoφhism in the NKIR gene in the human, which 30 diagnosis comprises determining the sequence of nucleic acid at one of more of positions: 2361 in exon 1 as defined by the position SEQ ID No. 1; 1371 in the promoter element as defined by the position in SEQ ID No. 1 ; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 5 495 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181 ; 600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; and determining the status of the human by reference to polymoφhism in the NKIR gene; and 10 (ii) administering an effective amount of a NKIR ligand antagonist. Preferably determination of the status of the human is clinically useful. Examples of clinical usefulness include deciding which antagonist drug of drugs to administer and/or in deciding on the effective amount of the drug or drugs. The NKIR ligand antagonist may optionally also have activity at the NK2R. 15 According to another aspect of the present invention there is provided use of an NKIR ligand antagonist drug in preparation of a medicament for treating a NKIR ligand mediated disease in a human diagnosed as having a single nucleotide polymoφhism at one or more of positions: 2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177; 20 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181. According to another aspect of the present invention there is provided use of an NKIR ligand antagonist drug in preparation of a medicament for treating a NKIR ligand mediated 25 disease in a human diagnosed as having a single nucleotide polymoφhism at one or more of positions: 2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 30 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181; 495 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181 ; 600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181. According to another aspect of the present invention there is provided use of an NKIR ligand antagonist drug in preparation of a medicament for treating a NKIR ligand mediated 5 disease in a human diagnosed as having a single nucleotide polymoφhism at one or more of positions: 2361 in exon 1 as defined by the position in SEQ ID No. 1 ; 1371 in the promoter element as defined by the position in SEQ ID No. 1 ; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 10 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 600 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181 ; 15 809 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181. According to another aspect of the present invention there is provided a pharmaceutical pack comprising an NKIR antagonist drug and instructions for administration of the drug to humans diagnostically tested for a single nucleotide polymoφhism at one or more of positions: 20 2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181. According to another aspect of the present invention there is provided a pharmaceutical 25 pack comprising an NKIR antagonist drug and instructions for administration of the drug to humans diagnostically tested for a single nucleotide polymoφhism at one or more positions: 2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 30 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 600 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181 ; 809 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181. According to another aspect of the present invention there is provided a pharmaceutical pack comprising an NKIR antagonist drug and instructions for administration of the drug to 5 humans diagnostically tested for a single nucleotide polymoφhism at one or more positions: 2361 in exon 1 as defined by the position in SEQ ID No. 1; 1371 in the promoter element as defined by the position in SEQ ID No. 1; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 10 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181 ; 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 600 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181; 809 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181. 15 Testing for the presence of the polymoφhism in exon 5 is especially preferred because, without wishing to be bound by theoretical considerations, of its resulting in a significant amino acid change in NKIR polypeptide (as explained herein). The nucleic acid sequences of the invention, particularly those relating to and identifying the single nucleotide polymoφhisms identified herein represent a valuable information source 20 with which to identify further sequences of similar identity and characterise individuals in terms of, for example, their identity, haplotype and other sub-groupings, such as susceptibility to treatment with particular drugs. These approaches are most easily facilitated by storing the sequence information in a computer readable medium and then using the information in standard macromolecular structure programs or to search sequence databases using state of the 25 art searching tools such as GCG (Genetics Computer Group), BlastX BlastP, BlastN, FASTA (refer to Altschul et al. J. Mol. Biol. 215:403-410, 1990). Thus, the nucleic acid sequences of the invention are particularly useful as components in databases useful for sequence identity, genome mapping, pharmacogenetics and other search analyses. Generally, the sequence information relating to the nucleic acid sequences and polymoφhisms of the invention may be 30 reduced to, converted into or stored in a tangible medium, such as a computer disk, preferably in a computer readable form. For example, chromatographic scan data or peak data, photographic scan or peak data, mass spectrographic data, sequence gel (or other) data. The invention provides a computer readable medium having stored thereon one or more nucleic acid sequences of the invention. For example, a computer readable medium is provided comprising and having stored thereon a member selected from the group consisting of: a nucleic acid comprising the sequence of a nucleic acid of the invention, a nucleic acid consisting of a nucleic acid of the invention, a nucleic acid which comprises part of a nucleic acid of the invention, which part includes at least one of the polymoφhisms of the invention, a set of nucleic acid sequences wherein the set includes at least on nucleic acid sequence of the invention, a data set comprising or consisting of a nucleic acid sequence of the invention or a part thereof comprising at least one of the polymoφhisms identified herein. The computer readable medium can be any composition of matter used to store information or data, including, for example, floppy disks, tapes, chips, compact disks, digital disks, video disks, punch cards and hard drives. In a particular embodiment of the invention there is provided a computer readable medium having stored thereon a member selected from the group consisting of: a nucleic acid comprising SEQ ID No. 1; a set of nucleic acids wherein at least one of said sequences comprises SEQ ID No. 1 ; a data set representing a nucleic acid sequence comprising SEQ ID No. 1; a nucleic acid consisting of SEQ ID No. 1; a set of nucleic acids wherein at least one of said sequences consists of the sequence of SEQ ID No. 1; a nucleic acid comprising any part (i.e. fragment of at least 20 bases) of a sequence selected from the group consisting of: SEQ ID No. 1, EMBL ACCESSION NO. X 65177, EMBL ACCESSION NO. X 65179, EMBL ACCESSION NO. X 65179 or EMBL ACCESSION NO. X 65181, which part includes at least one of the polymoφhisms identified herein. A computer based method is also provided for performing sequence identification, said method comprising the steps of providing a nucleic acid sequence comprising a polymoφhism of the invention in a computer readable medium; and comparing said polymoφhism containing nucleic acid sequence to at least one other nucleic acid or polypeptide sequence to identify identity (homology), i.e. screen for the presence of a polymoφhism. Such a method is particularly useful in pharmacogenetic studies and in genome mapping studies. In a particular embodiment of the invention there is provided a method for performing sequence identification, said method comprising the steps of providing a nucleic acid sequence comprising a sequence selected from the group consisting of: the nucleic acid sequence of SEQ ID No. 1 with T at position 2361 in exon 1 as defined by the position in SEQ ID No. 1; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with T at position 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with a single base deletion at position 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with a single base deletion at position 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with C at position 461 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with A inserted at position 495 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181 ; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with G at position 600 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with T at position 809 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of SEQ ID No. 1 with G at position 1371 in the promoter element as defined by the position in SEQ ID No. 1; or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at least one of the polymoφhisms; and comparing said nucleic acid sequence to at least one other nucleic acid or polypeptide sequence to identify identity. In another embodiment of the invention there is provided a method for performing sequence identification, said method comprising the steps of providing one or more of the following polymoφhism containing nucleic acid sequences: the nucleic acid sequence of SEQ ID No. 1 with T at position 2361 in exon 1 as defined by the position in SEQ ID No. 1; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with T at position 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with a single base deletion at position 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with a single base deletion at position 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with C at position 461 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with A inserted at position 495 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with G at position 600 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with T at position 809 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of SEQ ID No. 1 with G at position 1371 in the promoter element as defined by the position in SEQ ID No. 1 ; or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at least one of the polymoφhisms, in a computer readable medium; and comparing said nucleic acid sequence to at least one other nucleic acid or polypeptide sequence to determine identity. The invention will now be illustrated but not limited by reference to the following Examples. All temperatures are in degrees Celsius. In the Examples below, unless otherwise stated, the following methodology and materials have been applied. AMPLITAQ™, available from Perkin-Elmer Cetus, is used as the source of thermostable DNA polymerase. General molecular biology procedures can be followed from any of the methods described in "Molecular Cloning - A Laboratory Manual" Second Edition, Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory, 1989). Electropherograms were obtained in a standard manner: data was collected by ABI377 data collection software and the wave form generated by ABI Prism sequencing analysis (2.1.2). EXAMPLES Example 1 Identification of Polymorphisms 1. Methods DNA Preparation DNA was prepared from frozen blood samples collected in EDTA following protocol I (Molecular Cloning: A Laboratory Manual, p392, Sambrook, Fritsch and Maniatis, 2 nd Edition, Cold Spring Harbor Press, 1989) with the following modifications. The thawed blood was diluted in an equal volume of standard saline citrate instead of phosphate buffered saline to remove lysed red blood cells. Samples were extracted with phenol, then phenol/chloroform and then chloroform rather than with three phenol extractions. The DNA was dissolved in deionised water. Template Preparation Templates were prepared by PCR using the oligonucleotide primers and annealing 5 temperatures set out below. The extension temperature was 72° and denaturation temperature 94°. Generally 50 ng of genomic DNA was used in each reaction and subjected to 35 cycles of PCR. Exon 1 SEQ ID No. 1 2547 bp 10 A). Fragment Forward primer Reverse Primer Annealing Temp Time 2000-2467 2000-2019 2448-2467 58° 60s B). Fragment Forward Primer Reverse Primer Annealing Temp Time 15 1168-1712 1168-1187 1693-1712 58° 60s Exon 3 Accession Number X65179 373 bp Fragment Forward Primer Reverse Primer Annealing Temp Time 20 14-318 14-33 299-318 58° 60s Exon 5 Accession Number X65181 3929 bp Fragment Forward Primer Reverse Primer Annealing Temp Time 25 18-417 18-38 398-417 58° 60s For dye-primer sequencing these primers were modified to include Ml 3 forward and reverse primer sequences (ABI protocol P/N 402114, Applied Biosystems) at the 5' end of the forward and reverse oligonucleotides respectively. 30 Dye Primer Sequencing Dye-primer sequencing using Ml 3 forward and reverse primers was as described in the ABI protocol P/N 402114 for the ABI Prism™ dye primer cycle sequencing core kit with "AmpliTaq FS"™ DNA polymerase, modified in that the annealing temperature was 45° and DMSO was added to the cycle sequencing mix to a final concentration of 5 %. The extension reactions for each base were pooled, ethanol/sodium acetate precipitated, washed and resuspended in formamide loading buffer. 4.25 % Acrylamide gels were run on an automated sequencer (ABI 377, Applied Biosystems). 2. Results Exon 1 SEQ ID No. 1 A). Nucleotide 2361 C/T Phe (111 ) TTC/TTT Allele frequency TTC 47% TTT 53% To precisely identify the location of the 2361 polymoφhism, its relative location within SEQ ID No. 1 is as follows: TGCAAGTTCCACAACTTCTTCCCCATCGCCGCTGTCTTCGC (SEQ ID No.3) 2341 2361 2381 B). Nucleotide 1371 A/G Allele frequency (37 individuals) A 98.6% G 1.4 % The polymoφhism creates an recognition sequence (GGCCC) for the restriction enzyme, Sau 961 (New England Biolabs). A PCR product ( position 1168-1712, 544 bp) containing the wild type sequence (AGCCC) will not be cleaved by Sau 961 (New England Biolabs). Digestion of a heterozygote product (A/GGCCC) will generate products of 203 bp, 341 bp and 540 bp. Digestion of a homozygous variant (GGCCC) will generate products of 203 bp and 341 bp. Exon 3 Accession Number X 65179 Flanking intron Nucleotide 271 G/T Allele frequency G 98.5% T 1.5% Nucleotide 272 ΔA (note "Δ" indicates deletion) Frequency ΔA 4.5% To precisely identify the location of the 271 and 272 polymoφhisms, their relative locations within the X65179 wild-type sequence is as follows: AAGTCTCTGCCAAGCGCAAGGTGAGCAGGGGACAGGCAGA (SEQ ID No.4) 241 271 280 AAGTCTCTGCCAAGCGCAAGGTGAGCAGGGGACAGGCAGA (SEQ ID No.5) 241 272 280 The G271T polymoφhism creates a Rsal (GTAC) restriction enzyme recognition site. A PCR product (304 bp) containing the wild type sequence will not be digested by Rasl. Digestion of a heterozyote product will give bands of 304bp, 257bp and 47 bp. Digestion of a homozygous variant product will generate bands of 257 bp, 47 bp. The 272 ΔA polymoφhism creates a Cac 81 (GCNNGC) restriction enzyme recognition site. A PCR product (304 bp) containing the wild type sequence will not be digested by Cac 81. Digestion of a heterozyote product will give bands of 304bp, 258bp and 46 bp. Digestion of a homozygous variant product will generate bands of 258 bp, 46 bp. Exon 5 Accession Number X 65181 Nucleotide 245 ΔC 5 Frequency ΔC 1.5% This results in premature termination and loss of C-terminal 26 amino acids ... 379 380 381 382 379 10 S L D L S W T stop TCC CTG GAC CTG -» ... TCC TGG ACC TGA Unless otherwise indicated, all the allele frequencies were determined on the basis of analysis of 34 individuals. 15 Example 2 Identification of Polymorphisms 1. Methods All PCR conditions and sequencing protocols are as described in Example 1. Allele 20 frequencies were determined in a panel of 37 individuals. Template Preparation 3' UTR Accession Number X65181 Fragment Forward Primer Reverse Primer Annealing Temp Time 301-750 301-320 731-750 58° 60s 25 696-1144 696-715 1125-1144 58° 60s 2. Results 3' UTR Accession Number: X65181 Nucleotide 461 G/C Allele Frequency G 72% 30 C 28% This polymoφhism can be detected by digestion with restriction enzyme Dde I GTTAG... Ddel negative ....CTTAG... Dde I positive CAATC... ....GAATC... Nucleotide 495 A insertion Allele Frequency 1.4% Nucleotide 600 A/G Allele Frequency A 92% G 8% This polymoφhism can be detected by digestion with restriction enzyme Ban II ....AAGCCC. Ban II negative ...GAGCCC... Ban II positive ....TTCGGG.. ...CTCGGG.. Nucleotide 809 C/T Allele Frequency C 55% T 45% This polymoφhism can be detected by engineered restriction site Psp 14061 (AACGTT) Engineered primer 787-808 GGGTGAACAAAAGAAGGAACGT (SEQ ID No. 6) cooperating with the polymoφhism C/T to create the Psp 14061 (AACGTT) site only if the "T" polymoφhism is present in the target sequence.

Claims: CLAIMS What is claimed is: 1. A method for diagnosis of one or more single nucleotide polymoφhism(s) in NKIR 5 gene in a human, which method comprises determining the sequence of the nucleic acid of the human at one or more positions: 2361 in exon 1 as defined by the position in SEQ ID No. 1; 1371 in the promoter element as defined by the position in SEQ ID No.l; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 10 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 495 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181; 600 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181; 15 809 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181 ; and determining the status of the human by reference to polymoφhism in NKIR. 2. A method according to claim 1 in which the single nucleotide polymoφhism at position 2361 in exon 1 is presence of C and/or T, the single nucleotide polymoφhism at 20 position 1371 in the promoter element is presence of A and/or G, the single nucleotide polymoφhism at position 271 near exon 3 is presence of G and/or T, the single nucleotide polymoφhism at position 272 near exon 3 is presence of A and/or a single base deletion at this position, the single nucleotide polymoφhism at position 245 in exon 5 is presence of C and/or a single base deletion at this position, the single nucleotide polymoφhism at position 25 461 in the 3'UTR is presence of G and/or C, the single nucleotide polymoφhism at position 495 in the 3 'UTR is the presence of T and/or a single base insertion of A at this position, single nucleotide polymoφhism at position 600 in the 3 'UTR is presence of A and/or G, the single nucleotide polymoφhism at position 809 in the 3'UTR is presence of C and/or T. 30 3. A method as claimed in claim 1 or 2, wherein the region containing the potential polymoφhism is amplified by polymerase chain reaction prior to determining the sequence. 4. A method as claimed in any of claims 1 - 3, wherein the presence or absence of the polymoφhism is detected by reference to the loss or gain of, optionally engineered, sites recognised by restriction enzymes. 5 5. A method according to claim 1 or claim 2, in which the sequence is determined by a method selected from ARMS-allele specific amplification, allele specific hybridisation, oligonucleotide ligation assay and restriction fragment length polymoφhism (RFLP). 6. A method as claimed in any of the preceding claims for use in assessing the 10 predisposition and or susceptibility of an individual to diseases mediated by NKIR ligands. 7. A nucleic acid comprising any one of the following polymoφhism containing sequences: the nucleic acid sequence of SEQ ID No. 1 with T at position 2361 in exon 1 as defined by the 15 position in SEQ ID No. 1; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with T at position 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with a single base deletion at position 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 20 the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with a single base deletion at position 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with C at position 461 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181 ; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with A inserted at position 25 495 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181 ; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with G at position 600 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181 ; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with T at position 809 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; 30 the nucleic acid sequence of SEQ ID No. 1 with G at position 1371 in the promoter element as defined by the position in SEQ ID No. 1; or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at least one of the polymoφhisms. 8. A diagnostic nucleic acid primer capable of detecting a polymoφhism in the NKIR gene at one or more of positions: 2361 in exon 1 as defined by the position SEQ ID No. 1; 1371 in the promoter element as defined by the position SEQ ID No. 1; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181 ; 809 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181, in the NR1R gene. 9. A diagnostic primer as claimed in claim 8 which is an allele specific primer adapted for use in ARMS. 10. An allele-specific oligonucleotide probe capable of detecting a polymoφhism in the NKIR gene at one or more of positions: 2361 in exon 1 as defined by the position in SEQ ID No. 1; 1371 in the promoter element as defined by the position in SEQ ID No. 1; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181 ; 600 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181; 809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181, in the NRlR gene. 11. A diagnostic kit comprising one or more diagnostic primer(s) as defined in claim 8 or 9 and/or one or more allele-specific oligonucleotide probes(s) as defined in claim 10. 12. An allelic variant of human NKIR polypeptide having a C-terminal deletion of 26 amino acids. 13. A method of treating a human in need of treatment with an NKIR ligand antagonist 5 drug in which the method comprises: (i) diagnosis of a single nucleotide polymoφhism in the NKIR gene in the human, which diagnosis comprises determining the sequence of nucleic acid at one of more of positions: 2361 in exon 1 as defined by the position SEQ ID No. 1; 1371 in the promoter element as defined by the position in SEQ ID No. 1; 10 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 15 600 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181 ; 809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; and determining the status of the human by reference to polymoφhism in the NKIR gene; and (ii) administering an effective amount of a NKIR ligand antagonist. 20 14. Use of an NKIR ligand antagonist drug in preparation of a medicament for treating a NKIR ligand mediated disease, particularly asthma, in a human diagnosed as having a single nucleotide polymoφhism at one or more of positions: 2361 in exon 1 as defined by the position in SEQ ID No. 1 ; 25 1371 in the promoter element as defined by the position in SEQ ID No. 1 ; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 30 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 809 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181. 15. A pharmaceutical pack comprising an NKl R antagonist drug and instructions for administration of the drug to humans diagnostically tested for a single nucleotide polymoφhism at one or more positions: 2361 in exon 1 as defined by the position in SEQ ID No. 1 ; 5 1371 in the promoter element as defined by the position in SEQ ID No. 1; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 10 495 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181 ; 600 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181 ; 809 in the 3 ' UTR as defined by the position in EMBL ACCESSION NO. X65181. 16. A computer readable medium having stored thereon a member selected from the group 15 consisting of: a nucleic acid comprising SEQ ID No. 1; a set of nucleic acids wherein at least one of said sequences comprises SEQ ID No. 1; a data set representing a nucleic acid sequence comprising SEQ ID No. 1; a nucleic acid consisting of SEQ ID No. 1; a set of nucleic acids wherein at least one of said sequences consists of the sequence of SEQ ID No. 1; a nucleic acid comprising any part of a sequence selected from the group consisting of: SEQ 20 ID No. 1, EMBL ACCESSION NO. X 65177, EMBL ACCESSION NO. X 65179, EMBL ACCESSION NO. X 65179 or EMBL ACCESSION NO. X 65181, which part includes at least one of the polymoφhisms identified in claim 1. 17. A method for performing sequence identification, said method comprising the steps of 25 providing a nucleic acid sequence comprising a sequence selected from the group consisting of: the nucleic acid sequence of SEQ ID No. 1 with T at position 2361 in exon 1 as defined by the position in SEQ ID No. 1; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with T at position 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with a single 30 base deletion at position 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with a single base deletion at position 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with C at position 461 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with A inserted at position 495 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with G at position 600 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with T at position 809 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of SEQ ID No. 1 with G at position 1371 in the promoter element as defined by the position in SEQ ID No. 1; or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at least one of the polymoφhisms; and comparing said nucleic acid sequence to at least one other nucleic acid or polypeptide sequence to identify identity. 18. A method for performing sequence identification, said method comprising the steps of providing one or more of the following polymoφhism containing nucleic acid sequences: the nucleic acid sequence of SEQ ID No. 1 with T at position 2361 in exon 1 as defined by the position in SEQ ID No. 1; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with T at position 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with a single base deletion at position 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with a single base deletion at position 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with C at position 461 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with A inserted at position 495 in the 3 'UTR as defined by the position in EMBL ACCESSION NO. X 65181 ; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with G at position 600 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with T at position 809 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of SEQ ID No. 1 with G at position 1371 in the promoter element as defined by the position in SEQ ID No. 1 ; or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at least one of the polymoφhisms, in a computer readable medium; and comparing said nucleic acid sequence to at least one other nucleic acid or polypeptide sequence to determine identity.

Inventors: ANAND RAKESH, MORTEN JOHN EDWARD NORRIS, SMITH JOHN CRAIG, ANAND, RAKESH, MORTEN, JOHN, EDWARD, NORRIS, SMITH, JOHN, CRAIG
Applicants: ANAND RAKESH, MORTEN JOHN EDWARD NORRIS, SMITH JOHN CRAIG, ZENECA LTD, ANAND, RAKESH, MORTEN, JOHN, EDWARD, NORRIS, SMITH, JOHN, CRAIG, ZENECA LIMITED
Application year: 1999
Main classification: C12Q1
IPC codes: A61K45, A61P11, A61P43, C07K14, C12M1, C12N15, C12Q1, G01N33